Tumor microenvironment: the formation of the immune profile
Tumor microenvironment (TME) is formed as a result of interaction and cross-linking between the tumor cell and different types of surrounding cells. Recent studies have shown that the tumor reprograms the microenvironment so that TME promotes the development of primary tumors, their metastasis and b...
Saved in:
| Published in | Medit͡s︡inskai͡a︡ immunologii͡a Vol. 22; no. 2; pp. 207 - 220 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists
16.04.2020
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Tumor microenvironment (TME) is formed as a result of interaction and cross-linking between the tumor cell and different types of surrounding cells. Recent studies have shown that the tumor reprograms the microenvironment so that TME promotes the development of primary tumors, their metastasis and becomes an important regulator of oncogenesis. Under the influence of the tumor, the immune profile in the TME undergoes significant changes, “editing". An immunosuppressive network is formed, which suppresses the activity of the main effector of cellular immunity — T lymphocytes. T cells in TMA are in a state of anergy and exhaustion. T cells in TME are characterized by increased expression of inhibitory receptors, decreased secretion of cytokines and cytolytic activity. Blocking inhibitory receptors with specific antibodies can lead to the restoration of the functions of exausted T cells. Therefore, the restoration of the functional activity of T lymphocytes is one of the important strategies in cancer immunotherapy. The formation of the immune profile is influenced by genetic aberrations accumulating in the tumor. They play an important role in creating a specific, characteristic only for this tumor immune environment in the TME. Genetic changes in tumor cells lead to phenotypic and functional rearrangements of lymphocytes, which allows the tumor to escape the reaction of immune cells. Since many tumors occur after prolonged inflammation or exhibit characteristics of chronic inflammation as they progress, inflammation is considered an important factor in the formation of immune profile in TME. Immune infiltrates from different human tumors associated with inflammation may contain valuable prognostic and pathophysiological information. Macrophages in the TME now began to be regarded as descriptive marker and as a therapeutic target. One of the main mechanisms by which tumor cells reprogram surrounding cells is the release of exosomes — small vesicles that carry and deliver proteins and nucleic acids to other cells. When exosomal cargo is absorbed, molecular, transcriptional and translational changes occur in the recipient non-tumor cells in the TME. Therefore, tumor exosomes are an effective means by which the functions of immune cells in TME are purposefully changed. Thus, along with individual molecular and genomic testing of the tumor, attention should be paid to a deeper analysis of the immune profile of TME. It is a large resource of biomarkers and targets for immunotherapy. |
|---|---|
| AbstractList | Tumor microenvironment (TME) is formed as a result of interaction and cross-linking between the tumor cell and different types of surrounding cells. Recent studies have shown that the tumor reprograms the microenvironment so that TME promotes the development of primary tumors, their metastasis and becomes an important regulator of oncogenesis. Under the influence of the tumor, the immune profile in the TME undergoes significant changes, “editing". An immunosuppressive network is formed, which suppresses the activity of the main effector of cellular immunity — T lymphocytes. T cells in TMA are in a state of anergy and exhaustion. T cells in TME are characterized by increased expression of inhibitory receptors, decreased secretion of cytokines and cytolytic activity. Blocking inhibitory receptors with specific antibodies can lead to the restoration of the functions of exausted T cells. Therefore, the restoration of the functional activity of T lymphocytes is one of the important strategies in cancer immunotherapy. The formation of the immune profile is influenced by genetic aberrations accumulating in the tumor. They play an important role in creating a specific, characteristic only for this tumor immune environment in the TME. Genetic changes in tumor cells lead to phenotypic and functional rearrangements of lymphocytes, which allows the tumor to escape the reaction of immune cells. Since many tumors occur after prolonged inflammation or exhibit characteristics of chronic inflammation as they progress, inflammation is considered an important factor in the formation of immune profile in TME. Immune infiltrates from different human tumors associated with inflammation may contain valuable prognostic and pathophysiological information. Macrophages in the TME now began to be regarded as descriptive marker and as a therapeutic target. One of the main mechanisms by which tumor cells reprogram surrounding cells is the release of exosomes — small vesicles that carry and deliver proteins and nucleic acids to other cells. When exosomal cargo is absorbed, molecular, transcriptional and translational changes occur in the recipient non-tumor cells in the TME. Therefore, tumor exosomes are an effective means by which the functions of immune cells in TME are purposefully changed. Thus, along with individual molecular and genomic testing of the tumor, attention should be paid to a deeper analysis of the immune profile of TME. It is a large resource of biomarkers and targets for immunotherapy. |
| Author | Oleinik, V. M. Zhulai, G. A. Ignatiev, K. S. Shibaev, M. I. Oleinik, E. K. |
| Author_xml | – sequence: 1 givenname: E. K. orcidid: 0000-0001-9266-1129 surname: Oleinik fullname: Oleinik, E. K. organization: Institute of Biology, Karelian Research Centre, Russian Academy of Sciences – sequence: 2 givenname: M. I. surname: Shibaev fullname: Shibaev, M. I. organization: Republican Cancer Dispensary – sequence: 3 givenname: K. S. surname: Ignatiev fullname: Ignatiev, K. S. organization: Republican Cancer Dispensary – sequence: 4 givenname: V. M. surname: Oleinik fullname: Oleinik, V. M. organization: Institute of Biology, Karelian Research Centre, Russian Academy of Sciences – sequence: 5 givenname: G. A. surname: Zhulai fullname: Zhulai, G. A. organization: Institute of Biology, Karelian Research Centre, Russian Academy of Sciences |
| BookMark | eNo9kNFKwzAUhoNMcM49gTd9gWpOTtIkeiVD52DiTQXvQtommrE2I-0E395uk10d-Dl8P_93TSZd7Bwht0DvQEil70EUmNOCibx8K3PQVF-QKUPAXHL4nJDp-eGKzPt-QykFrhkWekoey30bU9aGOkXX_YQUu9Z1w0M2fLvMx9TaIcQui_4YhLbddy7bpejD1t2QS2-3vZv_3xn5eHkuF6_5-n25Wjyt85pRofNGFBQaVWmt68oilxYZUwK8Quu89QJQUoGCF07zhgmJyjtrCwuV8hIszsjqxG2i3ZhdCq1NvybaYI5BTF_GpiHUW2dkw6H2klUVMo66Vtw65VGPHaKpNYwsPLHGvX2fnD_zgJqjTnOwZQ62zKjTHHTiHx6PaWQ |
| CitedBy_id | crossref_primary_10_17650_2313_805X_2023_10_4_8_20 crossref_primary_10_17816_clinpract627504 crossref_primary_10_31793_1680_1466_2020_25_3_227 |
| Cites_doi | 10.3389/fcell.2017.00006 10.1038/nrclinonc.2016.217 10.1016/bs.acc.2015.12.005 10.1172/JCI69600 10.1038/nri3904 10.3389/fimmu.2016.00573 10.1016/j.cellimm.2017.04.005 10.1016/j.cell.2017.01.016 10.1038/cmi.2009.2 10.3389/fcell.2016.00083 10.1038/sj.icb.7100006 10.1126/science.aaa1348 10.1016/j.cell.2016.04.009 10.1038/nrclinonc.2015.215 10.18632/oncotarget.10290 10.1158/1078-0432.CCR-16-2128 10.1038/cr.2016.151 10.1016/j.juro.2015.02.2941 10.1080/2162402X.2017.1320626 10.1038/s41467-017-01018-0 10.3389/fimmu.2016.00032 10.1016/j.ccr.2014.03.021 10.1182/blood-2014-09-599423 10.1038/srep24120 10.1038/s41568-018-0081-9 10.1016/j.cell.2013.05.016 10.1038/nature21349 10.1016/j.immuni.2018.03.004 10.1038/ni.3589 10.1038/bjc.2014.367 10.1038/s41590-018-0298-5 10.1111/cei.12974 10.1172/JCI90962 10.1016/j.coi.2015.11.009 10.1080/2162402X.2017.1338230 10.1038/s41590-018-0114-2 10.1002/eji.201847659 10.1016/j.lungcan.2016.05.001 10.1016/j.smim.2018.10.011 10.1016/j.cellimm.2017.10.002 10.1038/s41568-019-0153-5 10.1038/cddis.2015.162 10.1158/1078-0432.CCR-16-2819 10.18632/oncotarget.3642 10.1038/s41568-019-0125-9 10.1111/cas.14069 10.1158/1541-7786.MCR-14-0387 10.1038/ni.3775 10.1155/2016/8941260 10.1126/science.aaa4971 10.1016/j.semcdb.2017.10.009 10.1038/leu.2017.91 10.1016/j.ccell.2017.06.003 10.1186/s40425-017-0244-3 10.1186/s12885-015-1742-7 10.1038/nri3862 10.1016/j.celrep.2017.08.078 10.1007/s12026-016-8798-6 10.1016/j.cell.2014.12.033 10.1001/jamaoncol.2016.1061 10.1038/nm.3773 10.1126/science.aar4060 10.4049/jimmunol.1402711 10.1002/JLB.3MR0717-292R 10.1038/nature23306 10.1038/s41590-019-0512-0 10.1038/nm.3909 10.1016/j.cell.2015.08.016 10.1038/nrc.2016.14 10.1016/j.clbc.2015.11.006 10.1038/s41568-018-0010-y 10.1002/stem.1934 10.1186/s12943-017-0597-8 10.1016/j.ejca.2016.02.026 10.1016/j.it.2015.02.008 10.1016/j.celrep.2016.12.019 10.3389/fmed.2015.00047 10.1089/scd.2013.0479 10.1038/ni.3384 10.1158/1078-0432.CCR-16-0732 10.1126/science.aad0095 10.1158/1078-0432.CCR-15-2879 |
| ContentType | Journal Article |
| DBID | AAYXX CITATION DOA |
| DOI | 10.15789/1563-0625-TMT-1909 |
| DatabaseName | CrossRef DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2313-741X |
| EndPage | 220 |
| ExternalDocumentID | oai_doaj_org_article_7d41cf72bb32439c84ae8f395135dc91 10_15789_1563_0625_TMT_1909 |
| GroupedDBID | 5VS 642 8FE 8FH AAYXX ACPRK ADBBV ALMA_UNASSIGNED_HOLDINGS BBNVY BCNDV BENPR CITATION GROUPED_DOAJ HCIFZ LK8 M7P PIMPY PROAC RIG |
| ID | FETCH-LOGICAL-c2059-d5601d8b999cba347a322851f83aefaf5137053546e94d25738feaa6a1b8f71a3 |
| IEDL.DBID | DOA |
| ISSN | 1563-0625 |
| IngestDate | Mon Nov 11 19:42:08 EST 2024 Fri Aug 23 02:06:15 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c2059-d5601d8b999cba347a322851f83aefaf5137053546e94d25738feaa6a1b8f71a3 |
| ORCID | 0000-0001-9266-1129 |
| OpenAccessLink | https://doaj.org/article/7d41cf72bb32439c84ae8f395135dc91 |
| PageCount | 14 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_7d41cf72bb32439c84ae8f395135dc91 crossref_primary_10_15789_1563_0625_TMT_1909 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-04-16 |
| PublicationDateYYYYMMDD | 2020-04-16 |
| PublicationDate_xml | – month: 04 year: 2020 text: 2020-04-16 day: 16 |
| PublicationDecade | 2020 |
| PublicationTitle | Medit͡s︡inskai͡a︡ immunologii͡a |
| PublicationYear | 2020 |
| Publisher | St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists |
| Publisher_xml | – name: St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists |
| References | ref13 ref57 ref12 ref56 ref15 ref59 ref14 ref58 ref53 ref52 ref11 ref55 ref10 ref54 ref17 ref16 ref19 ref18 ref51 ref50 ref46 ref45 ref48 ref47 ref42 ref86 ref41 ref85 ref44 ref43 ref49 ref8 ref7 ref9 ref4 ref3 ref6 ref5 ref82 ref81 ref40 ref84 ref83 ref80 ref35 ref79 ref34 ref78 ref37 ref36 ref31 ref75 ref30 ref74 ref33 ref77 ref32 ref76 ref2 ref1 ref39 ref38 ref71 ref70 ref73 ref72 ref24 ref68 ref23 ref67 ref26 ref25 ref69 ref20 ref64 ref63 ref22 ref66 ref21 ref65 ref28 ref27 ref29 ref60 ref62 ref61 |
| References_xml | – ident: ref22 doi: 10.3389/fcell.2017.00006 – ident: ref44 doi: 10.1038/nrclinonc.2016.217 – ident: ref80 doi: 10.1016/bs.acc.2015.12.005 – ident: ref29 doi: 10.1172/JCI69600 – ident: ref66 doi: 10.1038/nri3904 – ident: ref46 doi: 10.3389/fimmu.2016.00573 – ident: ref28 doi: 10.1016/j.cellimm.2017.04.005 – ident: ref40 doi: 10.1016/j.cell.2017.01.016 – ident: ref55 doi: 10.1038/cmi.2009.2 – ident: ref12 doi: 10.3389/fcell.2016.00083 – ident: ref26 doi: 10.1038/sj.icb.7100006 – ident: ref60 doi: 10.1126/science.aaa1348 – ident: ref75 doi: 10.1016/j.cell.2016.04.009 – ident: ref64 doi: 10.1038/nrclinonc.2015.215 – ident: ref45 doi: 10.18632/oncotarget.10290 – ident: ref6 doi: 10.1158/1078-0432.CCR-16-2128 – ident: ref70 doi: 10.1038/cr.2016.151 – ident: ref74 doi: 10.1016/j.juro.2015.02.2941 – ident: ref38 doi: 10.1080/2162402X.2017.1320626 – ident: ref50 doi: 10.1038/s41467-017-01018-0 – ident: ref85 doi: 10.3389/fimmu.2016.00032 – ident: ref69 doi: 10.1016/j.ccr.2014.03.021 – ident: ref82 – ident: ref2 doi: 10.1182/blood-2014-09-599423 – ident: ref20 doi: 10.1038/srep24120 – ident: ref47 doi: 10.1038/s41568-018-0081-9 – ident: ref14 doi: 10.1016/j.cell.2013.05.016 – ident: ref18 doi: 10.1038/nature21349 – ident: ref78 doi: 10.1016/j.immuni.2018.03.004 – ident: ref30 doi: 10.1038/ni.3589 – ident: ref52 doi: 10.1038/bjc.2014.367 – ident: ref86 doi: 10.1038/s41590-018-0298-5 – ident: ref81 doi: 10.1111/cei.12974 – ident: ref1 doi: 10.1172/JCI90962 – ident: ref7 doi: 10.1016/j.coi.2015.11.009 – ident: ref34 doi: 10.1080/2162402X.2017.1338230 – ident: ref4 doi: 10.1038/s41590-018-0114-2 – ident: ref71 doi: 10.1002/eji.201847659 – ident: ref13 doi: 10.1016/j.lungcan.2016.05.001 – ident: ref10 doi: 10.1016/j.smim.2018.10.011 – ident: ref27 doi: 10.1016/j.cellimm.2017.10.002 – ident: ref67 doi: 10.1038/s41568-019-0153-5 – ident: ref33 doi: 10.1038/cddis.2015.162 – ident: ref43 doi: 10.1158/1078-0432.CCR-16-2819 – ident: ref9 doi: 10.18632/oncotarget.3642 – ident: ref63 doi: 10.1038/s41568-019-0125-9 – ident: ref39 – ident: ref51 doi: 10.1111/cas.14069 – ident: ref56 doi: 10.1158/1541-7786.MCR-14-0387 – ident: ref24 doi: 10.1038/ni.3775 – ident: ref57 doi: 10.1155/2016/8941260 – ident: ref65 doi: 10.1126/science.aaa4971 – ident: ref73 doi: 10.1016/j.semcdb.2017.10.009 – ident: ref11 doi: 10.1038/leu.2017.91 – ident: ref77 doi: 10.1016/j.ccell.2017.06.003 – ident: ref19 doi: 10.1186/s40425-017-0244-3 – ident: ref32 doi: 10.1186/s12885-015-1742-7 – ident: ref79 doi: 10.1038/nri3862 – ident: ref36 doi: 10.1016/j.celrep.2017.08.078 – ident: ref17 doi: 10.1007/s12026-016-8798-6 – ident: ref62 doi: 10.1016/j.cell.2014.12.033 – ident: ref68 doi: 10.1001/jamaoncol.2016.1061 – ident: ref42 doi: 10.1038/nm.3773 – ident: ref58 doi: 10.1126/science.aar4060 – ident: ref21 doi: 10.4049/jimmunol.1402711 – ident: ref23 doi: 10.1002/JLB.3MR0717-292R – ident: ref61 doi: 10.1038/nature23306 – ident: ref5 doi: 10.1038/s41590-019-0512-0 – ident: ref25 doi: 10.1038/nm.3909 – ident: ref15 doi: 10.1016/j.cell.2015.08.016 – ident: ref53 doi: 10.1038/nrc.2016.14 – ident: ref31 doi: 10.1016/j.clbc.2015.11.006 – ident: ref41 doi: 10.1038/s41568-018-0010-y – ident: ref3 doi: 10.1002/stem.1934 – ident: ref59 doi: 10.1186/s12943-017-0597-8 – ident: ref83 doi: 10.1016/j.ejca.2016.02.026 – ident: ref49 – ident: ref54 doi: 10.1016/j.it.2015.02.008 – ident: ref16 doi: 10.1016/j.celrep.2016.12.019 – ident: ref48 doi: 10.3389/fmed.2015.00047 – ident: ref84 doi: 10.1089/scd.2013.0479 – ident: ref37 doi: 10.1038/ni.3384 – ident: ref76 doi: 10.1158/1078-0432.CCR-16-0732 – ident: ref35 – ident: ref72 doi: 10.1126/science.aad0095 – ident: ref8 doi: 10.1158/1078-0432.CCR-15-2879 |
| SSID | ssj0001492369 |
| Score | 2.1529727 |
| Snippet | Tumor microenvironment (TME) is formed as a result of interaction and cross-linking between the tumor cell and different types of surrounding cells. Recent... |
| SourceID | doaj crossref |
| SourceType | Open Website Aggregation Database |
| StartPage | 207 |
| SubjectTerms | exosomes heterogeneity immune profile suppression t lymphocytes tumor microenvironment tumors |
| Title | Tumor microenvironment: the formation of the immune profile |
| URI | https://doaj.org/article/7d41cf72bb32439c84ae8f395135dc91 |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8NAEF6kB_EiPrG-yMGjS5PsZh96UrEUoZ5S6G3ZJyi0ldL-f2eSWOLJi9dNCMk3u3zfkJlvCLkDzhEq9566oBnlKgXqco8FNgLomBfOh6ZA9l1MZvxtXs17o76wJqy1B26BG8nAC59k6RxQP9NecRtVYiAMWBW8bhOfXPeSqc9W95esmWcH-QmOLyirznIIdqge7RZpPa0pcKL-RUs99_6GZsZH5LDTh9lT-17HZG-9PSH70-4P-Cl5rLeL1TpbYB1dr0ntIQMhl-06EbNVahY-sPsjZt1g7jMyG7_WLxPaDUCgvgTZQwOmS0E5EHHeWcalheMHEikpZmOyCTCQ6M_CRdQ8wOFjKkVrhS2cSrKw7JwMlqtlvCBZLoV33EoAERQQXCubqTs-ulxb6fmQ3P98v_lqfS4M5gcIl0G4DMJlAC6DcA3JM2K0uxVNqpsFCJ3pQmf-Ct3lfzzkihyUmAKj_aK4JoPNehtvQCds3G2zJb4BqIO1WQ |
| link.rule.ids | 315,783,787,867,2109,27936,27937 |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tumor+microenvironment%3A+the+formation+of+the+immune+profile&rft.jtitle=Medit%CD%A1s%EF%B8%A1inskai%CD%A1a%EF%B8%A1+immunologii%CD%A1a&rft.au=Oleinik%2C+E.+K.&rft.au=Shibaev%2C+M.+I.&rft.au=Ignatiev%2C+K.+S.&rft.au=Oleinik%2C+V.+M.&rft.date=2020-04-16&rft.issn=1563-0625&rft.eissn=2313-741X&rft.volume=22&rft.issue=2&rft.spage=207&rft.epage=220&rft_id=info:doi/10.15789%2F1563-0625-TMT-1909&rft.externalDBID=n%2Fa&rft.externalDocID=10_15789_1563_0625_TMT_1909 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1563-0625&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1563-0625&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1563-0625&client=summon |